142 related articles for article (PubMed ID: 33663520)
1. TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas.
Xie S; Zhang Y; Peng T; Guo J; Cao Y; Guo J; Shi X; Li Y; Liu Y; Qi S; Wang H
Cancer Cell Int; 2021 Mar; 21(1):148. PubMed ID: 33663520
[TBL] [Abstract][Full Text] [Related]
2. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma.
Lin K; Taylor JR; Wu TD; Gutierrez J; Elliott JM; Vernes JM; Koeppen H; Phillips HS; de Sauvage FJ; Meng YG
PLoS One; 2011 Apr; 6(4):e18608. PubMed ID: 21559523
[TBL] [Abstract][Full Text] [Related]
3. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
7. Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas.
Song ZB; Yang HP; Xu AQ; Zhan ZM; Song Y; Li ZY
Chin Med J (Engl); 2020 Mar; 133(6):670-678. PubMed ID: 32197031
[TBL] [Abstract][Full Text] [Related]
8. TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease.
Masood M; Grimm S; El-Bahrawy M; Yagüe E
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371267
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome.
Bai Y; Zhang QG; Wang XH
Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217
[TBL] [Abstract][Full Text] [Related]
10. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
[TBL] [Abstract][Full Text] [Related]
11. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
[TBL] [Abstract][Full Text] [Related]
12. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
13. Systematic Analysis of 4-gene Prognostic Signature in Patients with Diffuse Gliomas Based on Gene Expression Profiles.
Huang C; Xiong Z; Yang Q; Li X
J Cancer; 2021; 12(14):4295-4306. PubMed ID: 34093830
[No Abstract] [Full Text] [Related]
14. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Activation of lncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma.
Wu X; Wan Q; Wang J; Hou P; Zhang Q; Wang Q; Lu X
Onco Targets Ther; 2022; 15():219-235. PubMed ID: 35299997
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
18. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
[No Abstract] [Full Text] [Related]
19. Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.
Zhang C; Meng W; Wang J; Lu Y; Hu G; Hu L; Ma J
Cell Mol Neurobiol; 2017 Aug; 37(6):1021-1027. PubMed ID: 27757741
[TBL] [Abstract][Full Text] [Related]
20. Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.
Xie Y; Tan Y; Yang C; Zhang X; Xu C; Qiao X; Xu J; Tian S; Fang C; Kang C
Cancer Biol Med; 2019 Nov; 16(4):784-796. PubMed ID: 31908895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]